Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by JohnnyUtah16on Mar 16, 2019 5:25pm
76 Views
Post# 29496477

RE:RE:RE:RE:RE:RE:RE:Meir Wins in Any Comparison

RE:RE:RE:RE:RE:RE:RE:Meir Wins in Any ComparisonHoly $hit you are stupid! I won't even acknowledge your name because you haven't contributed a single intelligent point to this conversation. Try to follow the conversation, I was talking about the current share price of GUD which is $8.01 following a 6% pop at the end of the day Friday. I was not talking about the price at 3:45 yesterday, which means nothing to me because the price is now higher. Just stay off the internet, thinking isn't your strong suit.

Anyway, great points MeirorValeant they have nothing to come back with. Pointless arguing with blind fools that lack the knowledge to understand a patient acquisition strategy. I'm outta here to enjoy the weather until we hear more good news about Goodman making Meir's life miserable by requesting thousands of documents from hiim before he'll look at his $hitty proposal. 
Bullboard Posts